To set the record straight: Orion is quite right on his...

To set the record straight: Orion is quite right on his recollection (albeit a single patient treated with PAT-SM6 in combination therapy). Particular mention is made of multiple myeloma lesions found in the testes which improved when this patient was dosed with PAT-SM6 dosed in combination!!

Melbourne, Australia; 28 May, 2014: Patrys Limited (ASX: PAB; “the Company”, a clinical stage biotechnology company, is pleased to announce the clinical results from a patient treated with PAT-SM6 in combination with other marketed multiple myeloma drugs.
The patient is a 61 yr old man with IgG kappa multiple myeloma diagnosed in 2013. Initially he was treated with four cycles of combination chemotherapy (Pomalyst, Adriamycin, Dexamethasone and high-dose Melphalan) followed by an autologous stem cell transplant (SCT). The patient initially responded well and went into complete remission (CR). Six months post SCT, the patient’s disease relapsed and he received another four cycles of combination chemotherapy including Revlimid. At the end of the four cycles, the patient suffered another relaspe of his disease with several extramedullary (outside of the bone marrow) tumours appearing. These tumours involved multiple soft tissues and the testes. There was also evidence of tumour within the bone-marrow (intramedullary).
Preclinical data have shown that Patrys’ PAT-SM6, when used in combination with several marketed myeloma drugs, induces specific binding and killing of multiple myeloma cells that are otherwise resistant to drug therapy. More specifically, PAT-SM6 has been shown to be highly synergistic with proteosome inhibitors (for example Velcade).
On the basis of these preclinical data, Professor Einsele (University of Würzburg Hospital) decided to treat the relapsed patient with a combination of Velcade, Revlimid and PAT-SM6. After three doses of this combination therapy, a PET-CT scan revealed significant shrinkage of both the extramedullary and the intramedullary lesions. Of particular note was the disappearance of the tumour in the testes. The patient has since gone on to receive additional treatment for his remaining disease.
Patrys CEO, Dr Marie Roskrow, commented “This patient, who has very difficult to treat myeloma, had an excellent response to PAT-SM6 when it was used with other myeloma drugs. The fact that he received a proteosome inhibitor (Velcade) as part of the treatment protocol with PAT-SM6 is particularly important as Patrys’ next clinical trial will be using a second generation proteosome inhibitor (Kyprolis (Carfilzomib)) in combination with PAT-SM6.